advertisement
Abstract #58516 Published in IGR 16-3
Prospects for lentiviral vector mediated prostaglandin F synthase gene delivery in monkey eyes in vivo
Lee ES; Rasmussen CA; Filla MS; Slauson SR; Kolb AW; Peters DM; Kaufman PL; Gabelt BT; Brandt CRCurrent Eye Research 2014; 39: 859-870
Currently, the most effective outflow drugs approved for clinical use are prostaglandin F2α analogues, but these require daily topical self-dosing and have various intraocular, ocular surface and extraocular side effects. Lentiviral vector-mediated delivery of the prostaglandin F synthase (PGFS) gene, resulting in long-term reduction of intraocular pressure (IOP), may eliminate off-target tissue effects and the need for daily topical PGF2α self-administration. Lentiviral vector-mediated delivery of the PGFS gene to the anterior segment has been achieved in cats and non-human primates. Although these results are encouraging, our studies have identified a number of challenges that need to be overcome for prostaglandin gene therapy to be translated into the clinic. Using examples from our work in non-human primates, where we were able to achieve a significant reduction in IOP (2 mm Hg) for 5 months after delivery of the cDNA for bovine PGF synthase, we identify and discuss these issues and consider several possible solutions.
Department of Ophthalmology, Institute of Vision Research, Yonsei University College of Medicine , Seoul , Korea .
Full articleClassification:
11.9 Gene therapy (Part of: 11 Medical treatment)
5.2 Primates (Part of: 5 Experimental glaucoma; animal models)
11.4 Prostaglandins (Part of: 11 Medical treatment)
